Shanghai Hile Bio-Technology Co., Ltd.

603718

CNE1000022T4

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-07-02 pm EDT			5-day change	1st Jan Change
6.22 ^CNY	-1.11%		-2.81%	-41.92%

Jun. 12	Shanghai Hile Bio-Technology Co., Ltd. agreed to acquire 55% stake in Shaanxi Reshine Biotech Co. Ltd. from Maylion Management Limited.	CI
Jun. 11	Shanghai Hile Bio-Technology to Buy 55% Stake in Bio-Tech Firm	CI

Shanghai Hile Bio-Technology to Buy 55% Stake in Bio-Tech Firm

June 11, 2024 at 08:15 am EDT

Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718) said it plans to buy 55% stake in bio-tech firm with estimated transaction amount of CNY 880 million - CNY 960 million ($121.31 million - $132.34 million).

Latest news about Shanghai Hile Bio-Technology Co., Ltd.

Shanghai Hile Bio-Technology Co., Ltd. agreed to acquire 55% stake in Shaanxi Reshine Biotech Co. Ltd. from Maylion Management Limited.	Jun. 11	CI
Shanghai Hile Bio-Technology to Buy 55% Stake in Bio-Tech Firm	Jun. 11	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Shanghai Hile Bio-Technology Co., Ltd.(XSSC:603718) added to S&P Global BMI Index	23-09-18	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Shanghai Zhizhuo Enterprise Management Consulting Co., Ltd. agreed to acquire Shanghai Caiyin Biotechnology Co., Ltd. from Shanghai Hile Bio-Technology Co., Ltd. for CNY 2 million.	23-04-11	CI
Shandong Sinder Technology Co., Ltd agreed to acquire Shandong Hile Biological Products Co., Ltd. from Shanghai Hile Bio-Technology Co., Ltd. for approximately CNY 110 million.	23-04-11	CI
Shanghai Hile Bio-Technology Plans to Sell Biological Products Unit	23-04-11	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-11	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Shandong Hile Biological Products Co., Ltd. announced that it has received CNY 140 million in funding from Shanghai Hile Bio-Technology Co., Ltd.	22-09-29	CI
Shandong Hile Biological Products Co., Ltd. announced that it expects to receive CNY 140 million in funding from Shanghai Hile Bio-Technology Co., Ltd.	22-08-29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-27	CI
WuXi Vaccines Inc. announced that it expects to receive $136 million in funding from Shanghai Hile Bio-Technology Co., Ltd., WuXi Biologics Inc.	21-05-12	CI
Yangling Jinhai Biotechnology Co., Ltd. announced that it has received CNY 85 million in funding from Shanghai Hile Bio-Technology Co., Ltd., Shanghai Runling Investment Partnership	21-04-28	CI
Shanghai Hile Bio-Technology Co., Ltd. completed the acquisition of 40% stake in Yangling Jinhai Biotechnology Co., Ltd. from Biogenesis Bago S.A. and Biogénesis Bagó Uruguay S.A.	21-04-28	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-23	CI
WuXi Biologics Cayman : , Shanghai Hile to Restructure Vaccine JV	21-04-02	MT
Shanghai Hile Bio-Technology Co., Ltd. intends to acquire 40% stake in Yangling Jinhai Biotechnology Co., Ltd. from Biogenesis Bago S.A. and Biogénesis Bagó Uruguay S.A. for CNY 56 million.	21-03-16	CI

Chart Shanghai Hile Bio-Technology Co., Ltd.

Duration

Period

Chart Shanghai Hile Bio-Technology Co., Ltd.

More charts

Company Profile

SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. is principally engaged in the research & development, production and sales of veterinary biological products. The Companyâs products mainly include escherichia coli (K88 and K99) gene modified vaccines for piglets, inactivated; porcine reproductive and respiratory syndrome vaccines, live and swine infectious atrophic rhinitis vaccines, inactivated; newcastle disease mild vaccines, living; newcastle disease, infectious bronchitis, egg drop syndromeâ76 vaccines, inactivated and infectious bronchitis vaccines, living, among others. The Company distributes its products mainly in China.

Sector

Pharmaceuticals

Calendar

01:30am - Extraordinary Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Sector Veterinary Drugs

	1st Jan change	Capi.
SHANGHAI HILE BIO-TECHNOLOGY CO., LTD.	-41.92%	563M
ELANCO ANIMAL HEALTH INCORPORATED	-5.17%	6.98B
BLUESTAR ADISSEO COMPANY	+21.62%	3.59B
VIRBAC	-4.17%	3.15B
VIMIAN GROUP AB	+12.16%	1.67B
VETOQUINOL SA	-9.08%	1.19B
JINYU BIO-TECHNOLOGY CO., LTD.	-34.91%	1.08B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-36.76%	1.05B
WUHAN KEQIAN BIOLOGY CO.,LTD	-32.83%	875M
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-17.45%	861M